Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3296110.26442/00403660.2019.02.000155Editorial articleПередовая статьяReview ArticleThe use of Tofacitinib in the treatment of inflammatory bowel diseaseМесто тофацитиниба в лечении воспалительных заболеваний кишечникаNasonovE LНасоновЕвгений Львович

д.м.н., академик РАН, научный руководитель ФГБНУ «НИИР им. В.А. Насоновой», проф. каф. ревматологии ИПО ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»

nasonov@irramn.ruAbdulganievaD IАбдулганиеваДиана Ильдаровна

д.м.н., проф., зав. каф. госпитальной терапии лечебного факультета ФГБОУ ВО КГМУ

FairushinaI FФайрушинаИрина Фанзиловна

аспирант каф. госпитальной терапии лечебного факультета ФГБОУ ВО КГМУ

V.A. Nasonova Research Institute of RheumatologyФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)Kazan State Medical University of the Ministry of Health of the Russian FederationФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России15022019912VOL 91, NO2 (2019)ТОМ 91, №2 (2019)10110811042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/32961

Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus kinase, JAK) involved in intracellular cytokine signaling. The review examines the molecular aspects of the JAK-STAT signaling pathway, justifying the use of the JAK-kinase inhibitor (tofacitinib) in the treatment of inflammatory bowel disease.

К крупным достижениям фармакологии XXI в. относится разработка нового класса лекарственных препаратов, представляющих собой низкомолекулярные, химически синтезированные молекулы (так называемые «малые молекулы»), точкой приложения которых являются Янус-киназы (Janus kinase, JAK), участвующие во внутриклеточной сигнализации цитокинов. В обзоре рассматриваются молекулярные аспекты сигнального пути JAK-STAT, обосновывающие использование ингибитора JAK-киназ тофацитиниба в терапии воспалительных заболеваний кишечника.

inflammatory bowel diseaseulcerative colitisCrohn's diseaseJAK inhibitorstofacitinibвоспалительные заболевания кишечникаязвенный колитболезнь Кронаингибиторы JAKтофацитинибOrdás I, Eckmann L, Talamini M, Baumgart D.C, Sandborn W.J. Ulcerative colitis. Lancet. 2012;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0Baumgart D.C, Sandborn W.J. Crohn's disease. Lancet. 2012;380(9853):1590-605. doi: 10.1016/S0140-6736(12)60026-9Park J.H, Peyrin-Biroulet L, Eisenhut M, Shin J.I. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017 Apr;16(4):416-26. doi: 10.1016/j.autrev.2017.02.013De Souza H.S, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13-27.Ahluwalia B, Moraes L, Magnusson M.K, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379-89. doi: 10.1080/00365521.2018.1447597Neurath M.F. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42.Chen M.L, Sundrud M.S. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflam Bow Dis. 2016;22(5):1157-67. doi: 10.1097/MIB.0000000000000714Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2(7):521-30. doi: 10.1016/S2468-1253(17)30031-6Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14(11):688. doi: 10.1038/nrgastro.2017.138Kalliolias G.D, Ivashkiv L.B. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49-62.Levin A.D, Wildenberg M.E, van den Brink G.R. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Aug;10(8):989-97. doi: 10.1093/ecco-jcc/jjw053. Epub 2016 Feb 19.Berns M, Hommes D.W. Anti-TNF-alpha therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opin Investigat Drug. 2016;25(2):129-43. doi: 10.1517/13543784.2016.1126247Dart R.J, Samaan M.A, Powell N, Irving P.M. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol. 2017;10:57-66.Amiot A, Grimaud J.C, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593-601. doi: 10.1016/j.cgh.2016.02.016. e2Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Ther Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X177Schwartz D.M, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-62. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.Winthrop K.L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234-43. doi: 10.1038/nrrheum.2017.23Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz D.M. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017 Apr;77(5):521-46. doi: 10.1007/s40265-017-0701-9Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно - практическая ревматология. 2014;52(2):209-21. doi: 10.14412/1995-4484-2014-209-221Baker K.F, Isaacs J.D. Novel therapies for immune - mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555Panés J, Sandborn W.J, Schreiber S, Sands B.E, Vermeire S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo - controlled trials. Gut. 2017;66(6):1049-59. doi: 10.1136/gutjnl-2016-312735Boland B.S, Vermeire S. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn’s Disease. Gastroenterol Clin North Am. 2017 Sep;46(3):627-44. doi: 10.1016/j.gtc.2017.05.015Soendergaard C, Bergenheim F.H, Bjerrum J.T, Nielsen O.H. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30122-0. doi: 10.1016/j.pharmthera.2018.07.003Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 Jul;13(7):693-703. doi: 10.1080/1744666X.2017.1291342Шапина М.В., Халиф И.Л. Эффективность и безопасность тофацитиниба при язвенном колите (обзор литературы). Колопроктология. 2018;65(3):94-102.Hammarén H.M, Virtanen A.T, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2018 Apr 20. pii: S1043-4666(18)30127-3. doi: 10.1016/j.cyto.2018.03.041Changelian P.S, Flanaan M.E, Ball D.J, et al. Prevention оf organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875-8.Flanagan M.E, Blumenkopf T.A, Brisette W.H, et al. Discovery of CP-690550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplantant rejection. J Med Chem. 2010;53:8468-84.Karaman M.W, Herrgard S, Treiber D.K, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-32.Meyer D.M, Jesson M.I, Li X, et al. Anti - inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant - induced arthritis. J Inflamm (Lond). 2010;7:41.Ghoreschi K, Jesson M.I, Li X, Lee J.L, Ghosh S, Alsup J.W, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-43. doi: 10.4049/jimmunol.1003668Hodge J.A, Kawabata T.T, Krishnaswami S, Clark J.D, Telliez J.B, Dowty M.E, Menon S, Lamba M, Zwillich S. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318.De Vries L.C.S, Wildenberg M.E, De Jonge W.J, D’Haens G.R. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Jul 1;11(7):885-93. doi: 10.1093/ecco-jcc/jjx003Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediat Inflam. 2017;2017:4810258. doi: 10.1155/2017/4810258Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-64.Ueno A, Ghosh A, Hung D, Li J, Jijon H. Th17 plasticity and its changes associated with inflammatory bowel disease. World J Gastroenterol. 2015 Nov 21;21(43):12283-95. doi: 10.3748/wjg.v21.i43.122Huber S, Gagliani N, Flavell R.A. Life, death, and miracles: Th17 cells in the intestine. Eur J Immunol. 2012;42:2238-45. doi: 10.1002/eji.201242619Hueber W, Sands B.E, Lewitzky S, Secukinumab in Crohn’s Disease Study Group, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double - blind placebo - controlled trial. Gut. 2012;61:1693-700.Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong R.W, Comer G.M, Cataldi F, Banerjee A, Maguire M.K, Li C, Rath N, Beebe J, Schreiber S. Randomised trial and open - label extension study of an anti - interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2017 Dec 15. pii: gutjnl-2017-314562. doi: 10.1136/gutjnl-2017-314562Fernández-Clotet A, Castro-Poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Rev Clin Immunol. 2018 Nov;14(11):881-92. doi: 10.1080/1744666X.2018.1532291Izzo R, Bevivino G, Monteleone G. Tofacitinib for the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2016;25:991-7.Sandborn W.J, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-24.Sandborn W.J, Su C, Sands B.E, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-36.Panés J, Vermeire S, Lindsay J.O, Sands B.E, Su C, et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Nov 8. doi: 10.1093/ecco-jcc/jjy135Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 Sep 10. pii: S1542-3565(18)30709-2. doi: 10.1016/j.cgh.2018.07.009Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta - analysis: comparative assessment of tofacitinib and biological therapies for moderate - to - severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454-65. doi: 10.1111/apt.14449Sandborn W.J, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 201;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, et al. Clinical remission in patients with moderate - to - severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double - blind, randomised, placebo - controlled trial. Lancet. 2017;389(10066):266-75. doi: 10.1016/S0140-6736(16)32537Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Ther Adv Gastroenterol. 2018 Jan 10;11:1756283X17745029.